Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hylastan · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Hylastan | DEVICE | - |
Inclusion Criteria: * Diagnosed with OA of the knee * Have tried but not been sufficiently helped by conservative treatment, such as weight reduction and pain medications Exclusion Criteria: * Prior or concomitant treatments that would impede measurement of safety and efficacy
Hylastan is used for osteoarthritis of the knee. It is an investigational treatment being studied in patients with symptomatic osteoarthritis of the knee, a condition involving joint pain and stiffness. The drug is currently in Phase 3 clinical development.
Hylastan is being developed by Sanofi, a global biopharmaceutical company. Sanofi's stock is traded under the ticker symbol SNY. The company is conducting clinical trials to evaluate the safety and efficacy of Hylastan for knee osteoarthritis.
Hylastan is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being evaluated for the treatment of symptomatic osteoarthritis of the knee.
Hylastan has one completed Phase 3 clinical trial with the identifier NCT00139295. The trial compared Hylastan to methylprednisolone acetate in patients with symptomatic osteoarthritis of the knee. It was a randomized, double-blind study conducted in the United States, Canada, France, Germany, and the United Kingdom.
No, Hylastan is not the same as methylprednisolone acetate. In the clinical trial NCT00139295, Hylastan was compared to methylprednisolone acetate, which served as the control treatment. Hylastan is an investigational drug for knee osteoarthritis, while methylprednisolone acetate is a corticosteroid used for comparison.